Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 14,947 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Digestive Disease Clear all
Completed Phase 4 Interventional

Safety of Manganese Restriction in Neonatal Parenteral Nutrition

NCT04259008
View directory record Official record
Conditions
Infant, Newborn, Disease
Interventions
Manganese omission, 5 mCg/kg/day manganese from "Multitrace-4 Neonatal."
Other
Lead sponsor
Sharp HealthCare
Other
Eligibility
Up to 1 Day
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 30, 2026, 12:54 AM EDT
Recruiting No phase listed Observational

Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database

NCT02897908
View directory record Official record
Conditions
Disease of Liver and Bile Duct
Interventions
vibration controlled transient elastography (VCTE)
Procedure
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

Survivorship Promotion In Reducing IGF-1 Trial

NCT02431676
View directory record Official record
Conditions
Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer, Melanoma of Skin, Endometrial Cancer, Liver Cancer, Pancreatic Cancer, Rectal Cancer, Kidney Cancer, Other Solid Malignant Tumors
Interventions
Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
Drug · Behavioral
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 30, 2026, 12:54 AM EDT
Terminated Not applicable Interventional

Ethibond Suture vs Vessel Loop as Draining Seton for Complex Anal Fistulas

NCT05933343
View directory record Official record
Conditions
Anal Fistula
Interventions
Ethibond suture, Vessel loop
Procedure
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 30, 2026, 12:54 AM EDT
Recruiting Not applicable Interventional

Serial MRI Scans During Radiation Therapy

NCT04188535
View directory record Official record
Conditions
Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme, Sarcoma
Interventions
MRI IMAGING
Diagnostic Test
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Enrolling by invitation No phase listed Observational

Shortwave Infrared Surgical Imaging Device Study

NCT07744425
View directory record Official record
Conditions
Cholecystitis, Cholecystitis, Chronic, Chronic Calculous Cholecystitis, Primary Hyperparathyroidism, Sigmoid Colon Diverticulitis, Multinodular Goiter, Thyroid and Parathyroid Surgery
Interventions
Observational study of SWIR imaging device in surgery
Device
Lead sponsor
Cision Vision, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
6
States / cities
Palo Alto, California • Evanston, Illinois • Glenview, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Enrolling by invitation No phase listed Observational

FAST (Focused Abbreviated Screening Technique)-MRI Study

NCT04539717
View directory record Official record
Conditions
Hepatocellular Carcinoma (HCC), Liver Cirrhosis
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
820 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
2
States / cities
Los Angeles, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 30, 2026, 12:54 AM EDT
Terminated Phase 2 Interventional

Evaluation of the Efficacy of Fomepizole in the Treatment of Acetaminophen Overdose

NCT05517668
View directory record Official record
Conditions
Acetaminophen, Drug Overdose, Acetaminophen Overdose, Acetaminophen Poisoning, Drug-induced Liver Injury, Liver Failure, Liver Toxicity
Interventions
Intravenous infusion of N-acetylcysteine, Intravenous infusion of Fomepizole (4-MP)
Drug
Lead sponsor
Richard Dart, MD, PhD
Other
Eligibility
10 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Oct 30, 2026, 12:54 AM EDT
Recruiting Phase 3 Interventional

PREcision MEDicine In Achalasia (PREMEDIA)

NCT07293650
View directory record Official record
Conditions
Type I Achalasia, Type II Achalasia, EGJ Outflow Obstruction Without Spastic/Hypercontractile Features
Interventions
Standard Myotomy, Tailored Short Myotomy
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
16
States / cities
Scottsdale, Arizona • La Jolla, California • Denver, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Enrolling by invitation No phase listed Observational

PillSense Use in Anemia and Hemoccult

NCT06951490
View directory record Official record
Conditions
Occult Gastrointestinal Bleeding, Upper Gastrointestinal Bleeding (UGIB)
Interventions
PillSense™
Device
Lead sponsor
AdventHealth
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

A Study of TMC435 in Combination With PSI-7977 (GS7977) in Chronic Hepatitis C Genotype 1-Infected Prior Null Responders To Peginterferon/Ribavirin Therapy or HCV Treatment-Naive Patients

NCT01466790
View directory record Official record
Conditions
Hepatitis C
Interventions
TMC435, PSI-7977 (GS7977), Ribavirin
Drug
Lead sponsor
Janssen R&D Ireland
Industry
Eligibility
18 Years to 70 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
22
States / cities
Hoover, Alabama • Bakersfield, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2015 · Synced Oct 30, 2026, 12:54 AM EDT
Terminated Not applicable Interventional

A Clinical Investigation Evaluating Peristeen® Performance

NCT05381610
View directory record Official record
Conditions
Neurogenic Bowel
Interventions
Peristeen
Device
Lead sponsor
Coloplast A/S
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 30, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional

A Study of Nuzefatide Pevedotin (BT5528) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

NCT07450859
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
nuzefatide pevedotin (BT5528)
Drug
Lead sponsor
BicycleTx Limited
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Completed Phase 4 Interventional Results available

Triple Combination Therapy in High Risk Crohn's Disease (CD)

NCT02764762
View directory record Official record
Conditions
Crohn Disease
Interventions
Vedolizumab, Adalimumab, Methotrexate
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 65 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
27
States / cities
Dothan, Alabama • Clearwater, Florida • Atlanta, Georgia + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 30, 2026, 12:54 AM EDT
Withdrawn Phase 2 Interventional

Treatment of Alcohol-Related Hepatitis With Arginine

NCT00200746
View directory record Official record
Conditions
Alcoholic Hepatitis
Interventions
Arginine
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2013 · Synced Oct 30, 2026, 12:54 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis

NCT02601300
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
GED-0301
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Newport Beach, California • San Diego, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Oct 30, 2026, 12:54 AM EDT
Active, not recruiting Phase 2 Interventional

RIC-NEC Randomized Controlled Trial

NCT05279664
View directory record Official record
Conditions
Necrotizing Enterocolitis
Interventions
Remote ischemic conditioning (RIC) + Standard of Care for NEC, Standard of Care for NEC
Other
Lead sponsor
The Hospital for Sick Children
Other
Eligibility
0 Weeks and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Completed Phase 2 Interventional

Study to Evaluate MET642 in Patients With NASH

NCT04773964
View directory record Official record
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
MET642, Placebo
Drug
Lead sponsor
Metacrine, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2024 · Synced Oct 30, 2026, 12:54 AM EDT
Completed Not applicable Interventional

Effects of Wolffia Globosa (Mankai) in Patients Undergoing Bariatric Surgery.

NCT03999632
View directory record Official record
Conditions
Bariatric Surgery Candidate, Diet Modification
Interventions
Dietary modification with introduction of Mankai
Other
Lead sponsor
Cleveland Clinic Florida
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated Feb 4, 2021 · Synced Oct 30, 2026, 12:54 AM EDT
Not yet recruiting Phase 2 Interventional

Oral N-acetylglucosamine in Crohn's Disease

NCT07225998
View directory record Official record
Conditions
Crohns Disease
Interventions
N-Acetylglucosamine (GlcNAc)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

BrUOG 379 Phase Ib/II Trial ONC201 + Nivolumab in MSS mCRC

NCT03791398
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Dose level 1 ONC201 625mg, Dose level 2 ONC201 500mg, Dose level 3 ONC201 375mg
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2023 · Synced Oct 30, 2026, 12:54 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer

NCT03165721
View directory record Official record
Conditions
Paraganglioma, Gastrointestinal Stromal Tumors, Carcinoma, Renal Cell, Renal Neoplasms, Pheochromocytoma
Interventions
SGI-110 (guadecitabine)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 99 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Completed Not applicable Interventional

Ritual Synbiotic+, a Dietary Supplement Designed to Impact Gastrointestinal Health, Mood, and Behavior in Women

NCT06834984
View directory record Official record
Conditions
Gastrointestinal Disease Symptoms
Interventions
Prebiotic, probiotic, postbiotic combination, Placebo
Dietary Supplement
Lead sponsor
Colorado State University
Other
Eligibility
25 Years to 65 Years · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 30, 2026, 12:54 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 30, 2026, 12:54 AM EDT